Access to benznidazole for Chagas disease in the United States-Cautious optimism?
Drugs for neglected tropical diseases (NTD) are being excessively priced in the United States. Benznidazole, the first-line drug for Chagas disease, may become approved by the Food and Drug Administration (FDA) and manufactured by a private company in the US, thus placing it at risk of similar prici...
Saved in:
| Main Authors: | Jonathan D Alpern, Rogelio Lopez-Velez, William M Stauffer |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2017-09-01
|
| Series: | PLoS Neglected Tropical Diseases |
| Online Access: | https://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0005794&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease.
by: Abilio Augusto Fragata-Filho, et al.
Published: (2016-03-01) -
Pharmacokinetic-pharmacodynamic modeling of benznidazole and its antitrypanosomal activity in a murine model of chronic Chagas disease.
by: Frauke Assmus, et al.
Published: (2025-05-01) -
Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.
by: Glaucia Diniz Alessio, et al.
Published: (2024-09-01) -
Amyloid immunotherapy for Alzheimer's disease: the case for cautious adoption
by: Jonathan M. Schott, et al.
Published: (2025-05-01) -
Redução dos Níveis de Insulina em Pacientes com Doença de Chagas Aguda na Amazônia Brasileira Tratados com Benznidazol
by: João Marcos Barbosa-Ferreira, et al.
Published: (2025-05-01)